Funding for this research was provided by:
Ministère de l’Enseignement Supérieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication (PHRCN-18-0311)
Received: 2 April 2020
Accepted: 5 May 2020
First Online: 3 June 2020
Ethics approval and consent to participate
: This trial has been accepted by an IRB in both France and Spain: Comité de protection des personnes Ile de France XI and Comité de Ética de la Investigación con medicamentos del Hospital Clínic de Barcelona.Authorization from Agence Nationale de Sécurité du Médicament and Comité National Informatique et Liberté was also obtained before the start of the trial.In France, since this is a cluster randomized trial with minimal risk and constraints, if a patient provides freely-given oral consent, he/she can be included in the study. In addition, the investigator will specify in the person’s medical file the person’s participation in the research and the procedures for obtaining his/her oral consent. In Spain, signed informed consent from the patient will be sought.
: Not applicable.
: The authors declare that they have no competing interests.